AC   CVCL_0144
SY   ARO 81-1; ARO81-1; ARO-81; ARO81; UCLA-RO 81; UCLA RO-81-A-1; UCLA RO-81A-1
DR   BTO; BTO:0002306
DR   MCCL; MCC:0000037
DR   BioSample; SAMN03151786
DR   BioSample; SAMN03151787
DR   cancercelllines; CVCL_0144
DR   CGH-DB; 55-1
DR   ChEMBL-Cells; CHEMBL3307996
DR   ChEMBL-Targets; CHEMBL612590
DR   Cosmic; 685603
DR   Cosmic; 755291
DR   Cosmic; 849972
DR   Cosmic; 886550
DR   Cosmic; 888094
DR   Cosmic; 888277
DR   Cosmic; 891254
DR   Cosmic; 913250
DR   Cosmic; 918184
DR   Cosmic; 931242
DR   Cosmic; 990532
DR   Cosmic; 1005458
DR   Cosmic; 1094760
DR   Cosmic; 1152116
DR   Cosmic; 1155329
DR   Cosmic; 1162836
DR   Cosmic; 1184761
DR   Cosmic; 1699417
DR   Cosmic; 2050371
DR   IARC_TP53; 2122
DR   PubChem_Cell_line; CVCL_0144
DR   TOKU-E; 4069
DR   Wikidata; Q54750547
RX   PubMed=2551628;
RX   PubMed=8423216;
RX   PubMed=11439348;
RX   PubMed=14522906;
RX   PubMed=15613457;
RX   PubMed=16924234;
RX   PubMed=18713817;
RX   PubMed=20143388;
RX   PubMed=21868764;
CC   Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland anaplastic carcinoma.
CC   From: Juillard G.J.-F.; University of California, Los Angeles; Los Angeles; USA.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00177.
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=8423216; PubMed=14522906).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): PubMed=18713817; PubMed=21868764
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 12,13
ST   D21S11: 30
ST   D3S1358: 15,17
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 10,16
ST   FGA: 20,22
ST   TH01: 6
ST   TPOX: 8,9
ST   vWA: 17,19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0320 ! HT-29
SX   Female
AG   44Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 32
RX   PubMed=2551628; DOI=10.1210/endo-125-4-1783;
RA   Pang X.-P., Hershman J.M., Chung M., Pekary A.E.;
RT   "Characterization of tumor necrosis factor-alpha receptors in human
RT   and rat thyroid cells and regulation of the receptors by
RT   thyrotropin.";
RL   Endocrinology 125:1783-1788(1989).
RX   PubMed=8423216; DOI=10.1172/JCI116168;
RA   Fagin J.A., Matsuo K., Karmakar A., Chen D.-L., Tang S.-H.,
RA   Koeffler H.P.;
RT   "High prevalence of mutations of the p53 gene in poorly differentiated
RT   human thyroid carcinomas.";
RL   J. Clin. Invest. 91:179-184(1993).
RX   PubMed=11439348; DOI=10.1038/sj.onc.1204531;
RA   Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.;
RT   "Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile
RT   response to hepatocyte growth factor.";
RL   Oncogene 20:3845-3856(2001).
RX   PubMed=14522906;
RA   Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R.,
RA   Vigneri P.;
RT   "p73 tumor-suppressor activity is impaired in human thyroid cancer.";
RL   Cancer Res. 63:5829-5837(2003).
RX   PubMed=15613457; DOI=10.1677/erc.1.00818;
RA   Onda M., Emi M., Yoshida A., Miyamoto S., Akaishi J., Asaka S.,
RA   Mizutani K., Shimizu K., Nagahama M., Ito K., Tanaka T., Tsunoda T.;
RT   "Comprehensive gene expression profiling of anaplastic thyroid cancers
RT   with cDNA microarray of 25 344 genes.";
RL   Endocr. Relat. Cancer 11:843-854(2004).
RX   PubMed=16924234; DOI=10.1038/sj.onc.1209899;
RA   Yu W., Imoto I., Inoue J., Onda M., Emi M., Inazawa J.;
RT   "A novel amplification target, DUSP26, promotes anaplastic thyroid
RT   cancer cell growth by inhibiting p38 MAPK activity.";
RL   Oncogene 26:1178-1187(2007).
RX   PubMed=18713817; DOI=10.1210/jc.2008-1102;
RA   Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M.,
RA   Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. III, Smallridge R.C.,
RA   Haugen B.R.;
RT   "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer
RT   cell lines reveals cross-contamination resulting in cell line
RT   redundancy and misidentification.";
RL   J. Clin. Endocrinol. Metab. 93:4331-4341(2008).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
RX   PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690;
RA   Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C.,
RA   Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G.,
RA   Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.;
RT   "Assembly and initial characterization of a panel of 85 genomically
RT   validated cell lines from diverse head and neck tumor sites.";
RL   Clin. Cancer Res. 17:7248-7264(2011).